All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | SEP 2025 2:1 split | SEP 2024 ~1.5:1 split | SEP 2023 | SEP 2022 ~1.4:1 split | SEP 2021 2:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $9 | $1 | – | – | – | – |
| Cost of Revenue | – | $1 | – | – | – | – |
| Gross Profit | – | $0 | – | – | – | – |
| General & Administrative | $16 | $40 | $30 | $27 | $21 | $13 |
| Research & Development | $25 | $27 | $42 | $26 | $42 | $39 |
| Total Operating Expenses | $50 | $68 | – | – | – | $52 |
| Operating Income | -$42 | -$67 | -$72 | -$53 | -$63 | -$52 |
| Non-Operating | ||||||
| Net Interest Expense | – | $0 | -$2 | -$2 | – | – |
| Other Non-Operating Income (Expense) | – | $3 | -$1 | -$4 | – | – |
| EBT (Earnings Before Tax) | -$48 | -$64 | -$75 | -$59 | -$66 | -$53 |
| Income Tax Expense | – | -$2 | $0 | $0 | $0 | $0 |
| Net Income | ||||||
| Net Income | -$45 | -$62 | -$75 | -$59 | -$66 | -$53 |
| Per Share Data | ||||||
| Revenue Per Share | $0.23 | $0.04 | – | – | – | – |
| EPS (Basic) | -$18.71 | -$1.79 | -$4.06 | -$4.72 | -$6.20 | -$7.00 |
| EPS (Diluted) | -$18.71 | -$1.79 | -$4.06 | -$4.72 | -$6.20 | -$7.00 |
| Weighted Avg Shares (Basic) | 37.0M | 34.8M | 18.5M | 250.2M | 212.1M | 152.7M |
| Weighted Avg Shares (Diluted) | 37.0M | 34.8M | 18.5M | 250.2M | 212.1M | 152.7M |
| Shares Outstanding | 37.0M | 34.8M | 18.5M | 12.5M | 10.6M | 7.6M |
Outlook Therapeutics (OTLK) financials: revenue, profit and margins
Outlook Therapeutics (OTLK) generated about n/a in revenue and -$61 million in net income (a -4,416.2% net margin) over the trailing twelve months, growing at roughly -23.0% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Outlook Therapeutics profitable?+
Outlook Therapeutics reported about -$61 million in net loss over the trailing twelve months, a net margin of roughly -4,416.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Outlook Therapeutics's profit margins?+
Outlook Therapeutics runs a gross margin of about 4.0%, an operating margin of about -4,744.3%, a net margin of about -4,416.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Outlook Therapeutics growing?+
Outlook Therapeutics's revenue has compounded at roughly -23.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside OTLK's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 14 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 19 Aug 2026. How this is calculated.
Fiscal year ends Sep.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with OTLK
Spot a number that looks wrong? Check it in OTLK's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OTLK
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.